Effects of Quetiapine on Sleep in Nonpsychiatric and Psychiatric Conditions

  title={Effects of Quetiapine on Sleep in Nonpsychiatric and Psychiatric Conditions},
  author={Jesse Wine and Cristina Sanda and Joshua Caballero},
  journal={Annals of Pharmacotherapy},
  pages={707 - 713}
Objective: To evaluate the use of immediate-release quetiapine for the treatment of insomnia. Data Sources: Pre-MEDLINE and MEDLINE were searched (1966 to October 2008) using the terms quetiapine, sleep, insomnia, and antipsychotics. Study Selection and Data Extraction: All studies and case reports evaluating insomnia as a primary endpoint were reviewed. Data Synthesis: The role of quetiapine for improving sleep in various patient populations is uncertain. Quetiapine has moderately sedative… 
Safety of Low Doses of Quetiapine When Used for Insomnia
Using low-dose quetiapine for insomnia is not recommended based on limited data and potential safety concerns, and serious adverse events identified included fatal hepatotoxicity, restless legs syndrome, akathisia, and weight gain.
Prescription Dose Analysis of Quetiapine in the Elderly and Insomnia
In the case of primary insomnia, quetiapine dose prescribed in the elderly patient group is higher than that in the non-elderly patient group, which is a relatively low dose prescribed compared to schizophrenia and bipolar disorder.
Quetiapine not quiet-a-pine--not a sleeper.
Long-term and Short-term Effects of Insomnia in Cancer and Effective Interventions
Insomnia is reviewed as a predisposing factor to cancer, prior to and during treatment, in cancer survivorship and in advanced cancer.
Quetiapine for sleep in patients with dementia.
  • C. Dolder, J. McKinsey
  • Medicine, Psychology
    The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists
  • 2010
Quetiapine prescribed as a sedative-hypnotic in patients with dementia, while common, is understudied and not without risk.
Pharmacologic treatment of insomnia.
  • T. Freedom
  • Medicine, Psychology
    Disease-a-month : DM
  • 2011
A case of dose escalation of quetiapine in persistent insomnia disorder
It is argued that in treatment-resistant insomnia, a high dose of quetiapine may be justifiable in selected cases but it is urged that further research on the long-term effects and potential adverse events ofQuetiAPine for this indication is of the utmost importance.
Sleep in Schizophrenia Patients and the Effects of Second Generation Antipsychotic Drugs
According to polysomnographic studies, the administration of clozapine, olanzapine and paliperidone to schizophrenia patients was followed by a significant reduction of SL and an increase of TST and stage S2, and with respect to risperidone, available information tends to indicate that the compound increases SWS.
Add-on Treatment of Quetiapine for Fibromyalgia: A Pilot, Randomized, Double-Blind, Placebo-Controlled 12-Week Trial
This trial sought to examine the efficacy and tolerability of quetiapine as a treatment for FM and its associated psychiatric symptoms, and observed significant benefits of drug treatment on sleep, uncertain effects on FM and mood symptoms, but no effects on pain.


Quetiapine for Insomnia in Parkinson Disease: Results From an Open-Label Trial
It is suggested that quetiapine may be a safe and effective treatment of insomnia in PD patients and double-blind studies will probably confirm these findings.
Sleep-promoting properties of quetiapine in healthy subjects
The sleep-improving properties of quetiapine may be important in counteracting different aspects of psychopathology in schizophrenia and other disorders and other mechanisms might be relevant as well and further investigation is required.
Night Locomotor Activity and Quality of Sleep in Quetiapine-treated Patients With Depression
It is found that changes of subjectively and objectively assessed sleep parameters do not necessarily reflect clinical improvement of depression during the same timeline, and despite partial clinical remission, objective sleep parameters still showed significantly different patterns compared with controls.
Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population.
It is demonstrated that atypical antipsychotic drugs improved subjective quality of sleep in patients with schizophrenia compared with conventional antipsychotics, suggesting that the marked potency of serotonin-2 receptor blockade in atypicals antippsychotic drugs may be involved in the mechanism of this improvement.
Quetiapine improves sleep disturbances in combat veterans with PTSD: sleep data from a prospective, open-label study.
Sleep data from a previously published study of quetiapine in PTSD suggested a decrease in the level of anxiety and anger experienced during the memories and nightmares of the trauma, and compared with healthy controls, PTSD patients had significantly worse global PSQI scores.
Quetiapine for Insomnia Associated with Refractory Depression Exacerbated by Phenelzine
This case illustrates that low-dose quetiapine may be an alternative treatment for phenelzine-associated insomnia, and despite the possibility that enhanced serotonergic activity might have resulted in serotonin syndrome, no adverse interactions between phenelZine and quetuapine were noted.
Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects
The significant reduction of nocturnal cortisol excretion following quetiapine reflects a decreased activity of the HPA-axis in healthy subjects and may be an important aspect in quetuapine’s mode of action in different patient populations.
Respiratory dysfunction in sleep apnea associated with quetiapine.
Respiratory function should be monitored when using quetiapine in patients with possible sleep apnea, particularly in obese patients and when given in combination with benzodiazepines.
Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use.
The most common diagnoses in patients receiving standing dose quetiapine were depressive disorders, followed by substance-related, bipolar, and psychotic disorders, and the most common prn dose was 50 mg, given for agitation or insomnia.